Analyst firms · Piper Sandler · ALGS
Piper Sandler ALGS price target and rating history
Aligos Therapeutics Inc. (ALGS) · Health Care
Piper Sandler rates Aligos Therapeutics Inc. (ALGS) Overweight with a $3 price target, as of its latest action on Jan 6, 2023. It has published 3 rating actions on ALGS since March 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a ALGS price target in the last 12 months, the median target is $45.
- Current rating
- Overweight
- Price target
- $3
- Median target, all firms
- $45
- Actions on ALGS
- 3
Piper Sandler price target on ALGS
Every Piper Sandler rating on ALGS
- Jan 6, 2023
- Mar 23, 2022
- Mar 11, 2022
How other firms rate ALGS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Lake Street | Buy | $45 | May 28, 2026 |
| Cantor Fitzgerald | Overweight | $20 | May 21, 2026 |
| Jefferies | Buy | $48 | Mar 19, 2026 |
Questions about Piper Sandler and ALGS
- What is Piper Sandler's price target for ALGS?
- Piper Sandler's latest stated price target for Aligos Therapeutics Inc. (ALGS) is $3, from its action on Jan 6, 2023.
- What is Piper Sandler's rating on ALGS?
- Piper Sandler rates ALGS Overweight, a bullish rating, as of Jan 6, 2023.
- When did Piper Sandler last change its view on ALGS?
- On Jan 6, 2023, Piper Sandler upgrades to Overweight from Neutral, price target $2 to $3.
- How does Piper Sandler's ALGS target compare with other analysts?
- Across 3 firms with a ALGS price target in the last 12 months, the median target is $45.
More ALGS rating histories
All Piper Sandler ratingsALGS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.